Tebra
Practice management and billing software for independent medical and dental clinics.
On the record
Checkpoint: First independent report of net revenue retention or churn since the $250M raise
The call
Tebra holds a large base of independent clinics through switching costs, but its AI story is unproven and revenue and valuation figures disagree by a wide margin.
Tebra makes scheduling and billing software that doctors use daily to run their practices, plus new AI tools to handle paperwork. It's hard for doctors to switch because their patient records and routines are locked in, but rivals like AdvancedMD and DrChrono offer similar software, and separate AI companies like Ambience and Abridge sell AI paperwork tools that work with any software. The big question is whether AI paperwork becomes cheap enough that doctors stop needing Tebra's version, especially if a rival software company partners closely with one of these AI companies to bundle them together.
Why
01
AI pressure: Ambience Healthcare, Abridge, Nuance DAX. These AI scribes sell straight into rival EHRs like AdvancedMD and DrChrono, so Tebra's AI features risk becoming table stakes, not a reason to switch. Could AI do the core job? Only partly.
02
Bigger players: eClinicalWorks. A larger, entrenched EHR player with more scale to absorb AI vendors and undercut Tebra on price for the same independent clinics. Could a giant copy it? Probably.
03
What protects it. Clinics rarely switch billing and records systems once staff are trained and claims are flowing, so churn stays low even without AI wins.
What would change this call
Ambience Healthcare or Abridge announces a deep integration with AdvancedMD or DrChrono. Would show AI scribe differentiation moving to Tebra's rivals, not Tebra.
Tebra discloses net revenue retention or logo churn figures in 2026. Would show whether the $250M raise is translating into retained growth.
Tebra's next funding round terms (valuation, debt vs equity mix) become public. Would clarify whether Dec 2025 round was a down round in disguise.
Tebra discloses net revenue retention or logo churn figures in 2026. Would show whether the $250M raise is translating into retained growth.
Tebra's next funding round terms (valuation, debt vs equity mix) become public. Would clarify whether Dec 2025 round was a down round in disguise.
Key numbers
- $250M raised, equity plus JPM debt
- 140,000+ providers on platform
- Headcount down 17.9%, 810 to 666
Named risks
- AI documentation specialists like Ambience and Abridge could commoditize Tebra's AI Note Assist differentiation.
- Conflicting third-party headcount data raises uncertainty about whether workforce is contracting or stable.
- JPMorgan debt facility from Dec 2025 round adds leverage if AI-driven revenue growth underdelivers.
- Fragmented market with multiple comparable EHR/PM vendors, no clear category leadership.
- Custom-quote pricing model criticized by third parties, potential retention or scrutiny risk.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Ambience Healthcare | contesting | Cleveland Clinic rolled out Ambience's AI documentation platform across 80+ specialties, Feb 2025 |
| Abridge | contesting | Sells AI documentation directly into any EHR, threatening to commoditize Tebra's AI Note Assist as of 2025-2026 |
| Nuance DAX | contesting | Point-solution AI scribe sellable into competing EHRs, pressuring Tebra's AI differentiation |
| AdvancedMD | contesting | Direct competitor in independent-practice EHR/PM market per SelectHub's 2026 alternatives list |
| DrChrono | contesting | Direct competitor in same EHR/PM segment for independent practices as of March 2026 |
| eClinicalWorks | contesting | Named direct competitor in fragmented independent-practice EHR market, March 2026 |
Questions people ask
- Is Tebra profitable?
- Tebra does not publicly disclose financials as a private company. In December 2025 it raised $250M in combined equity and JPMorgan debt financing to fund AI features, a structure suggesting an investment phase rather than confirmed profitability as of that date.
- Who owns Tebra?
- Tebra is privately held with no parent company, led by CEO Dan Rodrigues. Its December 2025 $250M round was led by existing investor Hildred Capital, with participation from Montreux Growth, Toba Capital, Transformation Capital, and HLM Venture Partners.
- Could AI replace Tebra?
- Tebra builds its own AI tools like AI Note Assist and AI Billing Assistant, expanded May 2026 with Custom AI Notes. But standalone scribe vendors Ambience Healthcare and Abridge sell directly into rival EHRs, risking commoditization of Tebra's AI differentiation rather than full replacement.
- Who is Tebra's biggest competitor?
- Tebra competes in a fragmented independent-practice EHR market. SelectHub's March 2026 competitor list names AdvancedMD, DrChrono, eClinicalWorks, athenahealth, and NextGen Healthcare as direct rivals, with no single dominant player.
- How much funding has Tebra raised?
- Tebra raised $65M in Series A financing in November 2021 tied to its founding merger, $72M in Series B funding in July 2022 at over $1B valuation, and $250M in combined equity and JPMorgan debt financing in December 2025 led by Hildred Capital.
- What is Tebra's AI strategy?
- Tebra's December 2025 $250M raise was explicitly framed as an AI acceleration round. CEO Dan Rodrigues called AI 'the great equalizer' for independent practices, funding tools like AI Note Assist, AI Billing Assistant, and an AI Voice Assistant.
Timeline
- 2026-05-20Tebra launches Custom AI Notes, extending AI Note Assist to custom clinical templates
- 2025-12-17Tebra secures $250M combined equity and JPMorgan debt round led by Hildred Capital for AI push
- 2025-02-19Cleveland Clinic rolls out Ambience Healthcare's AI documentation platform across 80+ specialties
- 2024-05-14PatientPop brand fully retired, merged into Tebra.com
- 2022-07Tebra raises $72M Series B led by Golub Capital, valuation tops $1B
- 2021-11-02Kareo and PatientPop merge to form Tebra with $65M Series A led by Golub Capital
Revision history
22 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Kareo and PatientPop Merge to Form Tebra (2021-11-02)
- Tebra secures more than $72 million at over $1 billion valuation
- Private Practice Platform Tebra Secures $250M to Accelerate AI Innovation (2025-12-17)
- Tebra - Headcount, Funding & Open Jobs (2026-06-27)
- $112.2M Est. ARR, $336.6M Valuation (2025-09-01)
- Tebra - Overview, News & Similar companies (2026-07-14)
- Employee Count & Headcount Data (2026-06-29)
- PatientPop completes final step in transformation to Tebra (2024-05-14)
- Tebra Pricing in 2026: Modules, Add-Ons, and Real Costs (2026-04-30)
- AI Note Assist: Office Visit (2026-05-28)
- Release Notes May 2026 (2026-05-20)
- The best AI medical scribes compared (2026-06-17)